WO2004012699A3 - Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent - Google Patents

Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent Download PDF

Info

Publication number
WO2004012699A3
WO2004012699A3 PCT/IN2003/000261 IN0300261W WO2004012699A3 WO 2004012699 A3 WO2004012699 A3 WO 2004012699A3 IN 0300261 W IN0300261 W IN 0300261W WO 2004012699 A3 WO2004012699 A3 WO 2004012699A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
particles containing
controlling agent
soluble active
matrix particles
Prior art date
Application number
PCT/IN2003/000261
Other languages
French (fr)
Other versions
WO2004012699A2 (en
Inventor
Navin Vaya
Rajesh Singh Karan
Sunil Sadanand Nadkarni
Vinod Kumar Gupta
Original Assignee
Torrent Pharmaceuticals Ltd
Navin Vaya
Rajesh Singh Karan
Sunil Sadanand Nadkarni
Vinod Kumar Gupta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd, Navin Vaya, Rajesh Singh Karan, Sunil Sadanand Nadkarni, Vinod Kumar Gupta filed Critical Torrent Pharmaceuticals Ltd
Priority to AU2003274680A priority Critical patent/AU2003274680A1/en
Publication of WO2004012699A2 publication Critical patent/WO2004012699A2/en
Publication of WO2004012699A3 publication Critical patent/WO2004012699A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Abstract

A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.
PCT/IN2003/000261 2002-08-05 2003-08-01 Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent WO2004012699A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274680A AU2003274680A1 (en) 2002-08-05 2003-08-01 Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN698MU2002 2002-08-05
IN698/MUM/2002 2002-08-05
IN696/MUM/2002 2002-08-05
IN696MU2002 2002-08-05
IN81MU2003 2003-01-22
IN81/MUM/2003 2003-01-22

Publications (2)

Publication Number Publication Date
WO2004012699A2 WO2004012699A2 (en) 2004-02-12
WO2004012699A3 true WO2004012699A3 (en) 2004-04-01

Family

ID=31499047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2003/000261 WO2004012699A2 (en) 2002-08-05 2003-08-01 Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent

Country Status (3)

Country Link
US (2) US8216609B2 (en)
AU (1) AU2003274680A1 (en)
WO (1) WO2004012699A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690853B2 (en) 2015-06-29 2023-07-04 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κβ for treatment of disease

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
JP5069395B2 (en) * 2002-02-21 2012-11-07 ヴァレアント インターナショナル （バルバドス） エスアールエル Pharmaceutical composition with improved release of at least one form of tramadol
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
MXPA05011557A (en) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Compositions for affecting weight loss.
DK1648421T3 (en) * 2003-07-24 2017-12-04 Glaxosmithkline Llc ORAL SOLUBLE MOVIES
CN1893956A (en) * 2003-07-25 2007-01-10 沃纳奇尔科特公司 Doxycycline metal complex in a solid dosage form
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
AR045347A1 (en) 2003-08-08 2005-10-26 Rovcal Inc HIGH CAPACITY ALKAL CELL
BRPI0418283A (en) * 2004-02-04 2007-05-02 Alembic Ltd prolonged release formulation and process for preparing an extended release formulation
JP2007520495A (en) 2004-02-06 2007-07-26 ボロディー トーマス ユリウス Use of aminosalicylic acid in diarrhea-type irritable bowel syndrome
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
EP1768652A1 (en) * 2004-05-21 2007-04-04 Lupin Ltd. Novel extended release composition of venlafaxine hydrochloride containing polyvinyl acetate
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
EP1855690B1 (en) * 2005-01-21 2016-06-01 Warner Chilcott Company, LLC A tetracycline metal complex in a solid dosage form
JP2008528607A (en) * 2005-01-26 2008-07-31 エラン・ファルマ・インターナショナル・リミテッド Controlled regulatory composition comprising an antipsychotic
MX2007009162A (en) 2005-01-28 2007-10-23 Euro Celtique Sa Alcohol resistant dosage forms.
US20100087546A1 (en) * 2005-04-20 2010-04-08 Biogenic Innovations, Llc Use of dimethyl sulfone (msm) to reduce homocysteine levels
WO2006119389A2 (en) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Quinine-containing controlled-release formulations
CA2615802C (en) * 2005-07-07 2015-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8480797B2 (en) * 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033082A2 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
JP5399072B2 (en) 2005-09-12 2014-01-29 アベラ ファーマスーティカルズ インコーポレイテッド System for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated therewith
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
PT2135603E (en) * 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Compositions and methods for increasing insulin sensitivity
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
WO2007093027A1 (en) * 2006-02-13 2007-08-23 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
RU2435569C2 (en) * 2006-03-16 2011-12-10 Трис Фарма, Инк. Compositions with modified release, containing complexes medication-ion-exchanging resin
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
WO2007120134A1 (en) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Lercanidipine modified release compositions
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CZ300698B6 (en) * 2006-06-16 2009-07-22 Zentiva, A. S. Metformin-containing tablet
US7811549B2 (en) * 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
JP2009543780A (en) * 2006-07-11 2009-12-10 ミューチュアル ファーマシューティカル カンパニー，インク． Controlled release formulations and kits
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20080248135A1 (en) * 2006-07-28 2008-10-09 Collegium Pharmaceutical, Inc. Combination Therapy for Otitis with Antiseptic and pH Adjustment
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
TWI609702B (en) 2006-11-09 2018-01-01 歐瑞根治療有限公司 Layered pharmaceutical formulations
US20080110792A1 (en) 2006-11-09 2008-05-15 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
FI20070521L (en) 2006-11-10 2008-05-11 Atacama Labs Oy Grains, tablets and granulation process
CA2618240C (en) 2006-11-17 2015-01-20 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
JP5721326B2 (en) * 2006-12-04 2015-05-20 スパーナス ファーマシューティカルズ インコーポレイテッド Enhanced immediate release formulation of topiramate
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US8067632B2 (en) 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CA2699806A1 (en) * 2007-09-18 2009-03-26 Niconovum Ab Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009092516A2 (en) * 2008-01-22 2009-07-30 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
CN101951902A (en) * 2008-02-28 2011-01-19 诺瓦提斯公司 Valsartan solid oral dosage forms and methods of making such formulations
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US8404701B2 (en) * 2008-03-27 2013-03-26 Chase Pharmaceuticals Corporation Use and composition for treating dementia
DK2805720T3 (en) 2008-05-28 2019-09-02 Reveragen Biopharma Inc Non-hormonal steroid modulators of NF-κB for the treatment of disease
WO2009158114A1 (en) * 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MX2010013169A (en) * 2008-06-02 2010-12-21 Reddy S Lab Ltd Modified release niacin formulations.
DE102008046650A1 (en) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapine-containing prolonged-release tablet
CA2736531C (en) * 2008-09-17 2016-10-25 Niconovum Ab Process for preparing snuff composition
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
BRPI0921494A2 (en) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd method of planning a underground forming sampling operation, method of controlling a underground forming sampling operation, method of controlling a drilling operation for an underground formation, and method of sampling during the drilling operation.
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
EA020477B1 (en) 2008-11-26 2014-11-28 Крка, Товарна Здравил, Д. Д., Ново Место Quetiapine composition
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
WO2011053874A1 (en) 2009-10-30 2011-05-05 Tandem Abela Development Group Llc Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
ES2686331T5 (en) 2009-11-23 2024-03-27 Cubist Pharmaceuticals Llc Lipopeptide compositions and related methods
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
SG183993A1 (en) * 2010-03-09 2012-10-30 Alkermes Pharma Ireland Ltd Alcohol resistant enteric pharmaceutical compositions
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
WO2011161504A1 (en) * 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
RU2624045C2 (en) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2809966C (en) * 2010-09-01 2019-01-08 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
KR20120092993A (en) * 2011-02-14 2012-08-22 지엘팜텍 주식회사 An oral sustained-release tablet comprising tianeptine or pharmaceutically acceptable salts thereof
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
KR20130024644A (en) * 2011-08-31 2013-03-08 한국유나이티드제약 주식회사 Controlled-release oral drug preparations and it's manufacturing process containing itopride hydrochloride
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US20150140089A1 (en) * 2012-05-08 2015-05-21 Metronomx Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
KR20210012056A (en) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. Methods of treating overweight and obesity
KR20140009819A (en) * 2012-07-13 2014-01-23 주식회사유한양행 Pharmaceutical composition for topical administration comprising vancomycin or its salt and dexamethasone phosphate or its salt
DK2884961T3 (en) 2012-08-15 2019-04-23 Tris Pharma Inc METHYLPHENIDATE TABLE WITH EXTENDED RELEASE
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
WO2014172568A2 (en) * 2013-04-17 2014-10-23 Morris Notelovitz Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
US10105358B2 (en) 2013-05-09 2018-10-23 Zeenar Enterprises Pty Ltd Niacin formulation
RU2017121505A (en) * 2014-12-01 2019-01-09 Сан Фармасьютикал Индастриз Лимитед COMPOSITION OF CEFPODOXYM PROXETYL WITH PROLONGED RELEASE
CN104546738B (en) * 2015-01-13 2017-08-08 上海信谊万象药业股份有限公司 The granulating coated technique of diltiazem hydrochloride in diltiazem hydrochloride sustained release tablets
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
ES2863500T3 (en) 2015-04-10 2021-10-11 Capsugel Belgium Nv Abiraterone Acetate Lipid Formulations
US20170035781A1 (en) 2015-06-22 2017-02-09 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
WO2018072709A1 (en) * 2016-10-19 2018-04-26 宁波西敦医药包衣科技有限公司 Dry powder coating composition of pharmaceutical micropellet
WO2018119108A1 (en) * 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Splid pharmaceutical formulations of asimadoline
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
GB201708224D0 (en) * 2017-05-23 2017-07-05 Juniper Pharmaceuticals Uk Ltd Device
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN108181419B (en) * 2017-11-24 2020-05-05 扬子江药业集团有限公司 Detection method of diethyl naphthalene cholamine raw material or preparation related substances thereof
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
EP3720435B1 (en) 2017-12-05 2024-03-06 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
BR112020025604A2 (en) 2018-06-15 2021-03-23 R.J. Reynolds Tobacco Company nicotine purification
CN108802248B (en) * 2018-06-21 2021-03-02 福州大学 Separation and analysis method of derivatized heparan sulfate disaccharide containing free amino
CA3114623C (en) 2018-09-28 2023-01-10 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
CN113395960A (en) 2018-11-19 2021-09-14 爵士制药爱尔兰有限公司 Anti-alcohol medicinal preparation
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
EP3980009A4 (en) 2019-06-04 2023-07-05 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN110124099B (en) * 2019-06-14 2022-01-11 四川涑爽医疗用品有限公司 Long-acting bacteriostatic compound periodontal plug treatment agent and preparation method thereof
CN115667235A (en) * 2019-11-18 2023-01-31 卡鲁娜治疗学有限公司 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
KR20230044231A (en) 2020-07-25 2023-04-03 파르마피나 일락 사티스 베 파자르라마 아노님 시르케티 Combination of drugs in parenteral dosage form for long-term anesthesia
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2023235542A1 (en) * 2022-06-03 2023-12-07 Atomic Pharmaceutics Inc. Unitary oral dosage form in base of spherical and/or spheroidal shaped particles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411326A2 (en) * 1989-06-30 1991-02-06 Bio-Dar Ltd. Microcapsules containing food additives and their use
WO2002003964A1 (en) * 2000-07-11 2002-01-17 Flamel Technologies Oral pharmaceutical composition with controlled release and prolonged absorption

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2566582A (en) 1950-04-08 1951-09-04 Irving E Rotner Headrest cover unit for dental chairs
US2968158A (en) 1955-08-08 1961-01-17 Upjohn Co New benzene sulfonyl ureas; composition and process for lowering blood sugar therewith
US3097242A (en) 1960-06-29 1963-07-09 Olin Mathieson Hydrindene sulfonylureas
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3668215A (en) 1967-11-25 1972-06-06 Bayer Ag Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups
CH505073A (en) 1968-04-26 1971-03-31 Hoffmann La Roche Sulphonylurea derivs hypoglycaemic
NL138933B (en) 1969-03-26 1973-05-15 Erba Carlo Spa PROCEDURE FOR PREPARING BENZENE SULPHONYLUREA DERIVATIVES WITH BLOOD SUGAR-MIRROR-LOWERING ACTION.
US3708486A (en) 1969-04-17 1973-01-02 Boehringer Sohn Ingelheim 2-(p-(n'-cycloalkyl-carbamido-n-sulfonyl)-phenethyl)-1,2,3,4-tetrahydro-1,3-dioxo-4,4-dimethyl-isoquinolines and alkali metal salts thereof
FR2045623A1 (en) * 1969-06-10 1971-03-05 Ruby Ets
US3957833A (en) 1970-03-23 1976-05-18 Hoffmann-La Roche Inc. Alkynyloxy-phenyl derivatives
US3801495A (en) 1972-05-19 1974-04-02 Chevron Res Integrated process combining catalytic cracking with hydrotreating
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6055078B2 (en) 1980-12-01 1985-12-03 日本新薬株式会社 Derivatives of moranoline
JPS6051189A (en) 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
JPS60172116A (en) * 1984-02-16 1985-09-05 三菱電機株式会社 Contact for vacuum breaker
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (en) 1984-10-03 1989-03-01 武田药品工业株式会社 The preparation method of thiazolidine diketone derivative
DK173350B1 (en) 1985-02-26 2000-08-07 Sankyo Co Thiazolidine derivatives, their preparation and pharmaceutical composition containing them
JPH06779B2 (en) 1985-06-10 1994-01-05 武田薬品工業株式会社 Thiazolidione derivative and pharmaceutical composition comprising the same
FR2585572B3 (en) 1985-07-31 1987-12-31 Hugelin Andre NOVEL PHARMACEUTICAL COMPOSITIONS BASED ON SALT OF P. CHLOROPHENOXYACETIC ACID FOR THE TREATMENT OF NEUROPATHIES AND PROVIDING NERVOUS REGENERATION
DE3856378T2 (en) 1987-09-04 2000-05-11 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix agent
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU650465B2 (en) 1990-07-03 1994-06-23 Yamanouchi Pharmaceutical Co., Ltd. Bisheterocyclic compound
EP0544696B1 (en) 1990-08-23 1995-01-11 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (en) 1990-12-06 1992-07-31 Terumo Corp Thiazolidine-2,4-dione derivative and treating agent for diabetic complication containing the same derivative
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
CA2106967C (en) 1991-04-11 2003-12-09 Takashi Sohda Thiazolidinedione derivatives, production and use thereof
IT1250421B (en) * 1991-05-30 1995-04-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES.
TW222626B (en) 1991-07-22 1994-04-21 Pfizer
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
US5589492A (en) 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
PL176885B1 (en) 1992-07-03 1999-08-31 Smithkline Beecham Plc Pharmaceutic composition
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
DE69831335T3 (en) 1997-06-06 2015-01-15 Depomed, Inc. MAGNIFYING ORAL DOSAGE FORMS OF WATER-SOLUBLE MEDICAMENTS WITH CONTROLLED RELEASE
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
CA2312990C (en) 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6296874B1 (en) 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
WO2002060043A1 (en) * 2001-01-23 2002-08-01 Koninklijke Philips Electronics N.V. A digitally controlled dc/dc converter

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411326A2 (en) * 1989-06-30 1991-02-06 Bio-Dar Ltd. Microcapsules containing food additives and their use
WO2002003964A1 (en) * 2000-07-11 2002-01-17 Flamel Technologies Oral pharmaceutical composition with controlled release and prolonged absorption

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROPHY M R ET AL: "Influence of coating and core modifications on the in vitro release of methylene blue from ethylcellulose microcapsules produced by pan coating procedure.", THE JOURNAL OF PHARMACY AND PHARMACOLOGY. ENGLAND AUG 1981, vol. 33, no. 8, August 1981 (1981-08-01), pages 495 - 499, XP009024692, ISSN: 0022-3573 *
PERUMAL D ET AL: "EFFECT OF FORMULATION VARIABLES ON IN VITRO DRUG RELEASE AND MICROMERITIC PROPERTIES OF MODIFIED RELEASE IBUPROFEN MICROSPHERES", JOURNAL OF MICROENCAPSULATION, TAYLOR AND FRANCIS INC. LONDON, GB, vol. 16, no. 4, July 1999 (1999-07-01), pages 475 - 487, XP000829605, ISSN: 0265-2048 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690853B2 (en) 2015-06-29 2023-07-04 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κβ for treatment of disease

Also Published As

Publication number Publication date
US7976871B2 (en) 2011-07-12
US20040096501A1 (en) 2004-05-20
US8216609B2 (en) 2012-07-10
AU2003274680A1 (en) 2004-02-23
WO2004012699A2 (en) 2004-02-12
AU2003274680A8 (en) 2004-02-23
US20060018933A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
ZA992951B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
WO2006056711A3 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
AU2002254036A1 (en) Taste masked pharmaceutical compositions
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
BR0207872A (en) Active agent release compound, composition, unit dosage form and method of administration
WO2005027843A3 (en) Chronotherapeutic dosage forms
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
WO2001010425A3 (en) Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
EP1238662A3 (en) Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
AU2002358676A1 (en) Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0303813A3 (en) Arylsulfonamides as antiviral agents, process for preparation of the compounds and pharmaceutical compositions containing them
WO2005065639A3 (en) Novel pharmaceutical compositions
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
WO2002015876A3 (en) Amorphous carrier materials for drug delivery
PL379465A1 (en) Sutained release formulation for venlafaxine hydrochloride
WO2002100338A3 (en) Compound and composition for delivering active agents
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
WO2004024128A3 (en) Modified release ketoprofen dosage form

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP